

# Wan Cheng Chow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6017003/publications.pdf>

Version: 2024-02-01

21  
papers

434  
citations

933447

10  
h-index

794594

19  
g-index

22  
all docs

22  
docs citations

22  
times ranked

855  
citing authors

#	ARTICLE	IF	CITATIONS
1	Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). <i>Gut</i> , 2022, 71, 854-863.	12.1	57
2	Clinical profile of non-alcoholic fatty liver disease in nonobese patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 257-261.	2.8	7
3	Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients. <i>Hepatology</i> , 2021, 74, 200-213.	7.3	29
4	Hepatitis C virus antigen detection is an appropriate test for screening and early diagnosis of hepatitis C virus infection in at-risk populations and immunocompromised hosts. <i>Journal of Medical Virology</i> , 2021, 93, 3738-3743.	5.0	3
5	Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 886-894.	2.4	3
6	Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. <i>Pharmacotherapy</i> , 2021, 41, 332-341.	2.6	3
7	Validation of the Expanded Baveno-VI Criteria for Screening Gastroscopy in Asian Patients with Compensated Advanced Chronic Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1343-1348.	2.3	3
8	Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 320-325.	2.8	23
9	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731.	3.9	32
10	Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up. <i>Microbiology Insights</i> , 2020, 13, 117863612091887.	2.0	13
11	A randomised clinical trial of the safety, cost effectiveness and patient experience of nurse-led telemonitoring of chronic hepatitis B patients. <i>GastroHep</i> , 2019, 1, 249-255.	0.6	2
12	Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. <i>Gastroenterology</i> , 2019, 156, 1862-1876.e9.	1.3	92
13	Fructose intake in patients with non-alcoholic fatty liver disease. <i>Proceedings of Singapore Healthcare</i> , 2019, 28, 218-223.	0.6	1
14	Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. <i>Singapore Medical Journal</i> , 2019, 60, 34-39.	0.6	12
15	Optimal liver stiffness measurement values for the diagnosis of significant fibrosis and cirrhosis in chronic liver disease in Singapore. <i>Singapore Medical Journal</i> , 2019, 60, 532-537.	0.6	7
16	Authors' reply: Comment on: Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. <i>Singapore Medical Journal</i> , 2019, 60, 323-323.	0.6	0
17	Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism. <i>Gastroenterology Report</i> , 2016, 5, gow033.	1.3	5
18	Perceptions of non-alcoholic fatty liver disease – an Asian community-based study. <i>Gastroenterology Report</i> , 2016, 4, 131-135.	1.3	38

#	ARTICLE	IF	CITATIONS
19	Change in model for end-stage liver disease score at two weeks, as an indicator of mortality or liver transplantation at 60 days in acute-on-chronic liver failure. <i>Gastroenterology Report</i> , 2015, 3, 122-127.	1.3	26
20	Reduction of HBV replication prolongs the early immunological response to IFN $\alpha$ therapy. <i>Journal of Hepatology</i> , 2014, 60, 54-61.	3.7	75
21	Risk of Hepatitis B Virus (HBV) Reactivation and Role of Anti-Viral Prophylaxis in Lymphoma Patients with Past HBV Infection (HBV Antigen negative but anti-Hepatitis B core antibody positive) Receiving Chemo-Immunotherapy. <i>Blood</i> , 2008, 112, 3768-3768.	1.4	3